Early Effect of Amyloid <i>β</i>-Peptide on Hippocampal and Serum Metabolism in Rats Studied by an Integrated Method of NMR-Based Metabolomics and ANOVA-Simultaneous Component Analysis

Du, Yao; Zheng, Hong; Xia, Huanhuan; Zhao, Liangcai; Hu, Wenyi; Bai, Guanghui; Yan, Zhihan; Gao, Hongchang

doi:https://doi.org/10.1155/2017/3262495

BioMed Research International

On this page

Abstract Introduction Materials and Methods Results Discussion Authors’ Contributions Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2017 | Article ID 3262495 | https://doi.org/10.1155/2017/3262495

Early Effect of Amyloid β-Peptide on Hippocampal and Serum Metabolism in Rats Studied by an Integrated Method of NMR-Based Metabolomics and ANOVA-Simultaneous Component Analysis

Yao Du,¹Hong Zheng,¹Huanhuan Xia,¹Liangcai Zhao,¹Wenyi Hu,¹Guanghui Bai,²Zhihan Yan,²and Hongchang Gao¹

Academic Editor: Mauro S. Oliveira

Received21 Jul 2016

Accepted27 Oct 2016

Published24 Jan 2017

Abstract

Amyloid β (Aβ) deposition has been implicated in the pathogenesis of Alzheimer’s disease. However, the early effect of Aβ deposition on metabolism remains unclear. In the present study, thus, we explored the metabolic changes in the hippocampus and serum during first 2 weeks of Aβ_25–35 injection in rats by using an integrated method of NMR-based metabolomics and ANOVA-simultaneous component analysis (ASCA). Our results show that Aβ_25–35 injection, time, and their interaction had statistically significant effects on the hippocampus and serum metabolome. Furthermore, we identified key metabolites that mainly contributed to these effects. After Aβ_25–35 injection from 1 to 2 weeks, the levels of lactate, N-acetylaspartate, creatine, and taurine were decreased in rat hippocampus, while an increase in lactate and decreases in LDL/VLDL and glucose were observed in rat serum. Therefore, we suggest that the reduction in energy and lipid metabolism as well as an increase in anaerobic glycolysis may occur at the early stage of Aβ_25–35 deposition.

1. Introduction

Alzheimer’s disease (AD) has been considered as a main cause of dementia [1]. In the world, there were 24.3 million people with dementia in 2001, and this number will be raised to 42.3 million in 2020 and 81.1 million by 2040 [2]. The two main pathological features of AD are amyloid plaques and neurofibrillary tangles [1]. At present, the wildly accepted pathogenesis of AD is the amyloid cascade hypothesis, which suggests that amyloid β (Aβ) deposition may trigger neuronal dysfunction and death in the brain [2]. In addition, AD has been associated with a metabolic disease accompanied by impairments in glucose utilization and energy metabolism [3]. Therefore, exploring the early impact of Aβ-peptide deposited in the hippocampus on metabolism will advance understanding of the onset and development of AD.

Metabolomics is a relatively new “omics” technique that attempts to profile all low-molecular weight metabolites in biomaterials and examines their changes induced by diseases. Metabolomics has been used as a promising tool to explore the metabolic mechanisms of AD in both human patients and animal models [4]. Modern analytical platforms that have been applied for metabolomic researches mainly include mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy [5]. The application of MS-based metabolomics has been reported to identify biomarkers for AD diagnosis [6–8], to monitor disease progression [9, 10], to investigate therapeutic response [11, 12], and to explore metabolic mechanisms [13–15]. Compared with mass spectrometry analysis, NMR spectroscopy as a commonly used analytical platform in metabolomics possesses several advantages, such as simple sample preparation, high reproducibility, and fast analysis. NMR-based metabolomics has been applied in exploring metabolic changes in urine, plasma, and brain of AD animal models [16, 17]. Moreover, selecting a suitable data analysis method is also of great importance for a metabolomic approach [18]. In this study, two factors, Aβ_25–35 injection and time, were included. Thus, ANOVA-simultaneous component analysis (ASCA) was selected, since it can not only include underlying multiple factors and their interaction, but also facilitate interpreting the effects of different factors [19]. ASCA model has been successfully applied to analyze metabolomic data; for example, Yde et al. [20] used ASCA to investigate the effects of dietary, time, and their interaction on plasma metabolome of pigs and identified different absorption patterns of betaine in response to different diets. ASCA was also used to examine different sources of variations, including dose, time, and dose/time interaction of bisphenol-A exposure, on serum metabolome, and found that energy and neurotransmitter metabolism were altered by bisphenol-A [21]. Recently, the effects of dairy intake, time, and their interaction were studied on the metabolic changes in urine, blood, and feces using ASCA [22], where it was reported that high dairy consumption may result in alterations in energy, protein, and gut microbial metabolism.

Aβ_25-35 is a peptide that exists in brain of AD patients [23]. In animals, Aβ_25-35-administration can result in neurodegeneration [24, 25], inflammatory response [25, 26], disordered neurotransmitter metabolism [27], and impaired synaptic plasticity [4] as well as spatial learning dysfunction [4, 28]. Therefore, Aβ_25-35 injected into the temporal cortex or hippocampus of animals has been commonly used to develop AD animal models [29]. In this study, we constructed AD rat models by injecting Aβ_25–35 into bilateral hippocampus and examined metabolic profiles in hippocampus and serum after 1 and 2 weeks of Aβ_25–35 injection using NMR-based metabolomics. Then, ASCA model was used to analyze the effects of Aβ_25–35 injection, time, and their interaction on metabolic changes in hippocampus and serum of rats and identify metabolites related to these effects.

2. Materials and Methods

2.1. Animals

Adult male Sprague-Dawley (SD) rats (body weight = g) were purchased from the SLAC Laboratory Animal Co. Ltd. (Shanghai, China) and kept in a specific pathogen-free colony at the Laboratory Animal Center of Wenzhou Medical University (Wenzhou, China). All rats were housed in metabolic cages with regulated temperature and humidity as well as a 12/12 h light-dark cycle with lights on at 8:00 a.m. and free access to standard rat chow and tap water. The present study was conducted according to the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Wenzhou Medical University.

2.2. Brain Stereotaxic Aβ_25–35 Injection

Sixty SD rats were weighted and randomly divided into Aβ_25-35 injected (AD) and control (Con) groups (30 rats for each group). After a 12 h fasting, rats were anesthetized with chloroform (3 mL/kg of body weight) and then placed on the stereotaxic apparatus to inject Aβ_25-35 solution into bilateral hippocampus CA1. Aβ_25-35 (Sigma Aldrich, St. Louis, MO, USA) solution was prepared by dissolving in saline at 5 mg/mL and incubating at 37°C for 7 days. Firstly, we cleaned rats’ scalp by iodine solution and then incised on the midline to expose the skull. After that, two holes were drilled on both sides of the middle line (3.0 mm posterior to bregma, 2.2 mm lateral to sagittal suture, and 2.9 mm beneath the surface of brain, A/P 3.0, M/L 2.2, and D/V 2.9 [30]), followed by injecting 2 μL of Aβ_25-35 solution at the rate of 0.2 μL/min. At the end of injection, the cannula was left for additional 5 min to allow sufficient diffusion of Aβ_25-35 into the hippocampus. Rats in control group were treated with the same procedure but injected with saline.

2.3. Morris Water Maze (MWM) Test

The MWM test was performed to evaluate learning and memory ability in rats at 1 week after Aβ_25-35 injection based on our previous method [31]. In brief, a circular pool with a diameter of 110 cm and a height of 30 cm was used and filled with opaque water at °C. The escape platform with a diameter of 7 cm was submerged 1 cm below the surface of the water. During a 4-day training period (4 trials/day), rats were guided to reach the escape platform by the operator, if they were not able to get it within 60 s. Then, the trained rats were subjected to a 90 s probe test without the escape platform. The swimming path, mean velocity, and the number of crossings over the original platform location were recorded using a computer system.

2.4. Sample Collection and Preparation

The rat was sacrificed by decapitation at 1 and 2 weeks after Aβ_25-35 injection. The hippocampus was isolated immediately, frozen using liquid nitrogen, and stored at −80°C until analysis. The hippocampus tissue was extracted according to our previous method [31]. In brief, the frozen brain tissue was weighed into an Eppendorf tube, and 4 mL/g of cold methanol and 0.85 mL/g of cold water were added into the sample tube. After homogenizing, 2 mL/g of cold chloroform and 2 mL/g of cold water were added into the mixture. Then, the mixture was homogenized using a vortex mixer, placed on ice for 15 min, and centrifuged at 10,000 ×g at 4°C for 15 min. Finally, the supernatant was carefully transferred into a new Eppendorf tube, lyophilized for 24 h, and stored at −80°C until NMR analysis. The dried extract was redissolved in 500 μL of D₂O containing 0.50 mM sodium trimethylsilyl propionate-d4 (TSP) and transferred to a 5 mm tube for NMR analysis.

Blood samples were collected from tail vein at 1 and 2 weeks after injection, centrifuged at 3,000 ×g at 4°C for 15 min to obtain serum, and stored at −80°C until NMR analysis. Prior to NMR analysis, 200 μL of serum was thawed and diluted with 250 μL of phosphate buffer (0.2 mM Na₂HPO₄/NaH₂PO₄, pH 7.4) to minimize pH variations and with 50 μL of D₂O for field frequency locking. Subsequently, the diluted serum was centrifuged at 12,000 ×g at 4°C for 10 min. Then, 500 μL of supernatant was transferred into a 5 mm NMR tube for NMR analysis.

2.5. NMR-Based Metabolomic Analysis

¹H NMR spectra were recorded using a Bruker AVANCE III 600 NMR spectrometer at 37°C. The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence was applied to reduce broad NMR signals from proteins and lipids. The main acquisition parameters were set as follows: acquisition time, 2.65 sec per scan; data points, 64 K; spectral width, 12,000 Hz; relaxation delay, 2 sec.

NMR spectra were manually phase/baseline-corrected and referenced to TSP peak at 0.00 ppm using Topspin software (v2.1 pl4, Bruker Biospin, Germany). All spectra were aligned using the “icoshift” procedure in MATLAB (R2012a, The Mathworks Inc., Natick, MA, USA) [32]. The spectral regions from 0.0 to 4.5 ppm for hippocampal sample and from 0.0 to 4.2 ppm for serum sample were subdivided and integrated to binning data with a size of 0.01 ppm for further multivariate analysis. The NMR signals were assigned using the Chenomx NMR suite 7.0 (Chenomx Inc., Edmonton, Canada) and the Human Metabolome Database [33] as well as the reported data on brain tissue [31] and serum [34].

2.6. ANOVA-Simultaneous Component Analysis (ASCA)

The ASCA model, which combines analysis of variance (ANOVA) and simultaneous component analysis (ACA), was used in this study. Two factors, Aβ_25-35 injection (AD and Con) and time (1 and 2 weeks), were included in the ASCA model. Firstly, the data matrix (, where is the number of samples and is the number of variables) was separated into matrices for Aβ_25-35 injection and time and for interaction between the two factors as well as a matrix with residuals , as shown in where is the overall means.

Then, matrices , , and were decomposed into score matrices , , and , loading matrices , , and , respectively, and a residual matrix as given inwhere is the overall means, , , and are the score (loading) matrices of Aβ_25-35 injection, time, and their interaction, respectively, and is the residual matrix.

All data were Pareto-scaled and analyzed by the ASCA model using ASCA toolbox (http://www.bdagroup.nl/Home.php) under MATLAB environment (R2012a, The Mathworks Inc., Natick, MA, USA). Moreover, the ASCA model was validated by a permutation test.

3. Results

3.1. Impaired Learning and Memory in Rats after Aβ_25–35 Injection

In order to assess the ability of spatial learning and memory of rats, the MWM test was concluded at 1 week after Aβ_25-35 injection. During a 4-day training period, the escape latency in the AD rats was significantly longer than that in the Con rats on day 4 (Figure 1(a)), while no significant difference was observed in mean swimming velocity between them (Figure 1(b)). Figure 1(c) illustrates the swimming trajectory of the AD and Con rats in the probe test of the MWM test. It can be seen that the AD rats cannot easily cross over the original platform location relative to the Con group (Figure 1(c)). Moreover, we can see that the AD rats had significantly lower percentages of total swimming length (Figure 1(d)) and time (Figure 1(e)) in the original platform area than the Con rats. Taken together, the MWM results revealed that spatial learning and memory ability was impaired in rats after Aβ_25-35 injection.

(a)

(b)

(c)

(d)

(e)

3.2. ¹H NMR Metabolite Profiles of Hippocampus and Serum in Rats

Figures 2(a) and 2(b) display typical ¹H NMR spectra of hippocampus samples obtained from the AD and Con rats, respectively. A total of 13 metabolites were identified, involving energy metabolism (Cre, creatine; Suc, succinate; Ala, alanine; Lac, lactate), neurotransmitters (Asp, aspartate; Glu, glutamate; Gln, glutamine; GABA, γ-aminobutyric acid; Gly, glycine), and membrane metabolism (Cho, choline; NAA, N-acetylaspartate) as well as osmoregulation (Myo, myoinositol; Tau, taurine). In addition, Figures 3(a) and 3(b) illustrate typical ¹H NMR spectra of serum samples obtained from the AD and Con rats, respectively, and 12 metabolites were identified, such as energy metabolism (glucose; For, formate; Cre, creatine; Ala, alanine; Lac, lactate), amino acid metabolism (His, histidine; Tyr, tyrosine; Gln, glutamine; Val, valine), and lipid metabolism (LDL/VLDL, low-density and very low-density lipoproteins) as well as glycoprotein (NAG, N-acetylglycoprotein; OAG, O-acetylglycoprotein).

(a)

(b)

(c)

(d)

Figure 2

Effect of Aβ_25–35 injection on hippocampal metabolism in rats analyzed by ASCA model: typical ¹H NMR spectra in rat hippocampus after injection of (a) saline (b) and Aβ_25-35 solutions; (c) ASCA score plot of the interaction effect of Aβ_25–35 injection and time as well as (d) its corresponding loading plot. Con, the control group with saline injection; AD, the AD group with Aβ_25–35 injection; Ala, alanine; Lac, lactate; GABA, γ-aminobutyric acid; NAA, N-acetylaspartate; Gln, glutamine; Glu, glutamate; Suc, succinate; Asp, aspartate; Cre, creatine; Cho, choline; Tau, taurine; m-Ins, myoinositol.

(a)

(b)

(c)

(d)

Figure 3

Effect of Aβ_25–35 injection on serum metabolism in rats analyzed by ASCA model: typical ¹H NMR spectra in rat serum after injection of (a) saline (b) and Aβ_25-35 solutions; (c) ASCA score plot of the interaction effect of Aβ_25–35 injection and time as well as (d) its corresponding loading plot. Con, the control group with saline injection; AD, the AD group with Aβ_25–35 injection; LDL/VLDL, low-density lipoproteins and very low-density lipoproteins; Val, valine; Lac, lactate; Ala, alanine, NAG, N-acetylglycoprotein; OAG, O-acetylglycoprotein; Gln, glutamine; Cre, creatine; Tyr, tyrosine; His, histidine; For, formate.

3.3. Identification of Metabolic Changes in the Hippocampus and Serum of Rats after Aβ_25–35 Injection Using ASCA

Table 1 lists values of ASCA models validated by 10,000-permutation test including the effects of Aβ_25-35 injection, time, and their interaction (Aβ_25-35 injection × time). We found significant effects of Aβ_25-35 injection on the metabolite profiles in both the hippocampus () and serum (). In addition, significant time effects were also observed on the hippocampus () and serum () metabolome. Most interestingly, there were significant interaction effects of Aβ_25-35 injection and time on the hippocampus () and serum () metabolome, and the corresponding ASCA score and loading plots are illustrated in Figures 2 and 3, respectively. Figure 2(d) shows that the levels of Lac, NAA, Cre, and Tau in the hippocampus were decreased after Aβ_25-35 injection from 1 to 2 weeks, relative to the Con group. In the serum, we found an increase in Lac as well as a decrease in LDL/VLDL and glucose after Aβ_25-35 injection from 1 to 2 weeks (Figure 3(d)).

4. Discussion

Amyloid β-peptide (Aβ) has been reported to induce oxidative stress in brain and thereby cause the onset and development of AD [35]. Therefore, injection of toxic Aβ into brain has been commonly used to construct AD animal model [36]. In the present study, we injected Aβ_25-35 into hippocampal area CA1 of rats and expectedly found an impaired ability of spatial learning and memory after 1 week using the Morris water maze test. Exploring the early effect of Aβ_25-35 deposited in the hippocampus on metabolism will achieve a better understanding of the onset and development of AD, but it has not been reported. Therefore, we examined the metabolic changes during first 2 weeks of Aβ_25-35 injection in the hippocampus and serum of rats using an integrated method of NMR-based metabolomics and ASCA model.

4.1. Effect of Aβ_25–35 Injection on Hippocampal Metabolism of Rats

The brain is vulnerable to energy metabolism deficit due to its high energy consumption [37]. In general, glucose is the main substrate for brain energy metabolism [38]. However, the astrocyte-neuron lactate shuttle (ANLS) hypothesis reported that glucose is mainly metabolized to Lac in astrocytes and then transported to neurons as the primary fuel [39]. Afterwards, Lac as a neuronal energy source was also confirmed in both in vitro [40] and in vivo [41] studies. In the present study, however, we found a reduction of Lac level in rat hippocampus after Aβ_25-35 injection from 1 to 2 weeks compared with that in the Con rats. In addition, Cre also plays an important role in maintaining the high energetic demand for brain development and functions via the creatine kinase/phosphocreatine system [42, 43]. Like Lac, a decreased level of Cre was also observed in rat hippocampus after Aβ_25-35 injection from 1 to 2 weeks, suggesting an insufficient supply of energy in the brain of the AD rats. A lower Cre level was also found in the hippocampus of another AD model, TgCRND8 mice [44]. Growing evidences have supported the concept that AD is a metabolic disease with impaired energy metabolism [45–47]. Moreover, González-Domínguez et al. [48] have also found that impaired energy metabolism is a key cause in pathogenesis of Alzheimer. Therefore, a reduction in energy metabolism in the hippocampus may be implicated in the onset and development of AD.

NAA has been regarded as a marker of neuronal density and integrity, since it is exclusively synthesized in the mitochondria of neurons [49, 50]. We found that NAA level was reduced in rat hippocampus after Aβ_25-35 injection relative to the Con group from 1 to 2 weeks, indicating that hippocampal neurons may be damaged during the progress of AD in rats. Previous findings have also shown that the level of NAA was decreased in neurodegenerative diseases, such as Alzheimer’s disease and Huntington’s disease [51–53]. Lalande et al. [54] also found a reduction of NAA in Tg2576 mice at one month of age relative to the age-matched wild-type mice. Tau is an important indicator of astrocyte as well as a regulator of osmotic pressure [55, 56]. Meanwhile, it also acts as an antioxidant in neuroprotection [57, 58]. In this study, compared with the Con group, a decrease in hippocampal Tau level in rats after Aβ_25-35 injection from 1 to 2 weeks may reflect the reduction of astrocyte activity and antioxygenation in the hippocampus. A similar finding was also obtained in the hippocampus of TgCRND8 mice [44]. Taken together, decreased levels of NAA and Tau may indicate that astrocytes and neurons in the hippocampus were damaged during AD development in rats.

4.2. Effect of Aβ_25–35 Injection on Serum Metabolism of Rats

In this study, VLDL/LDL, glucose, and lactate in serum were identified as the main metabolites induced by Aβ_25-35 injection using an integrated analytical method of NMR-based metabolomics and ASCA model. The initiation and acceleration of AD pathology have been closely associated with the downregulation of lipid metabolism [59, 60]. In the current study, we found that the serum level of lipoprotein, VLDL/LDL, was reduced after Aβ_25-35 injection from 1 to 2 weeks as compared with the Con group. Lipoprotein particles are lipid transporters in blood, so our finding may indicate a reduction of lipid metabolism in the AD rats. De La Monte et al. [45] found that lipid derivatives including phospholipids and sphingomyelins were significantly decreased in APP/PS1 mice. Glucose is the predominant energy substrate that can be oxidized to CO₂ and H₂O through tricarboxylic acid (TCA) cycle or transformed into lactate by anaerobic glycolysis. In this study, an increase in lactate level and a decrease in glucose level were found in the serum after Aβ_25-35 injection from 1 to 2 weeks, indicating that anaerobic glycolysis was upregulated during AD development. Using ¹H NMR-based metabolomic approach, similar results were also observed in APP/PS1 [7] and senescence-accelerated mouse prone 8 (SAMP8) [46] mice. In addition, compared with the wild-type mice, De La Monte et al. [45] found reduced glucose and increased lactate in serum of the APP/PS1 mice using a MS-based metabolomic approach. Therefore, serum metabolomics analysis reveals that a decrease in lipid metabolism and an increase in anaerobic glycolysis may be associated with the development of AD in rats.

In conclusion, the early effect of Aβ_25-35 deposition on hippocampal and serum metabolism was explored by an integrated analytical method of NMR-based metabolomics and ASCA model. Our results revealed that a series of metabolic disorders occurred at the early stage of Aβ_25-35 deposition, including reduction in energy metabolism in the hippocampus as well as a decrease in lipid metabolism and an increase in anaerobic glycolysis in the serum. However, several limitations in the present study should be considered: these findings should be confirmed by the use of multidose Aβ_25-35 and other animal models; only a few metabolites induced by Aβ_25-35 injection were identified, so we suggest using a multianalytical platform for drawing a more detailed metabolic pathway; measuring key proteins/enzymes in metabolic pathways will advance understanding of the metabolic mechanism underlying the onset and development of AD.

Competing Interests

The authors declare that they have no conflict of interests.

Authors’ Contributions

Hongchang Gao, Liangcai Zhao, Zhihan Yan, and Hong Zheng contributed to experimental design. Yao Du and Huanhuan Xia contributed to animal experiment and NMR analysis. Yao Du, Hong Zheng, and Hongchang Gao contributed to data analysis, result interpretation, and writing. All authors have read, revised, and approved the final manuscript. Yao Du and Hong Zheng contributed equally to this work.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (nos. 21575105 and 81501303) and Natural Science Foundation of Zhejiang Province (nos. LY14H090014, LY15H180010, and LY16H180009).

References

K. Blennow, M. J. de Leon, and H. Zetterberg, “Alzheimer's disease,” Lancet, vol. 368, no. 9533, pp. 387–403, 2006.
View at: Publisher Site | Google Scholar
C. P. Ferri, M. Prince, C. Brayne et al., “Global prevalence of dementia: a Delphi consensus study,” The Lancet, vol. 366, no. 9503, pp. 2112–2117, 2005.
View at: Publisher Site | Google Scholar
S. M. De la Monte, “Type 3 diabetes is sporadic Alzheimer's disease: mini-review,” European Neuropsychopharmacology, vol. 24, no. 12, pp. 1954–1960, 2014.
View at: Publisher Site | Google Scholar
E. Trushina and M. M. Mielke, “Recent advances in the application of metabolomics to Alzheimer's Disease,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1842, no. 8, pp. 1232–1239, 2014.
View at: Publisher Site | Google Scholar
A. Zhang, H. Sun, P. Wang, Y. Han, and X. Wang, “Modern analytical techniques in metabolomics analysis,” Analyst, vol. 137, no. 2, pp. 293–300, 2012.
View at: Publisher Site | Google Scholar
R. González-Domínguez, T. García-Barrera, and J. L. Gómez-Ariza, “Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry,” Journal of Pharmaceutical & Biomedical Analysis, vol. 98, pp. 321–326, 2014.
View at: Publisher Site | Google Scholar
R. Casanova, S. Varma, B. Simpson et al., “Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals,” Alzheimer's & Dementia, vol. 12, no. 7, pp. 815–822, 2016.
View at: Publisher Site | Google Scholar
K. Inoue, H. Tsuchiya, T. Takayama et al., “Blood-based diagnosis of Alzheimer's disease using fingerprinting metabolomics based on hydrophilic interaction liquid chromatography with mass spectrometry and multivariate statistical analysis,” Journal of Chromatography B, vol. 974, pp. 24–34, 2015.
View at: Publisher Site | Google Scholar
R. González-Domínguez, A. García, T. García-Barrera, C. Barbas, and J. L. Gómez-Ariza, “Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry,” Electrophoresis, vol. 35, no. 23, pp. 3321–3330, 2014.
View at: Publisher Site | Google Scholar
G. Paglia, O. Miedico, A. Cristofano et al., “Distinctive pattern of serum elements during the progression of Alzheimer's disease,” Scientific Reports, vol. 6, article 22769, 2016.
View at: Publisher Site | Google Scholar
H. Chu, A. Zhang, Y. Han et al., “Metabolomics approach to explore the effects of Kai-Xin-San on Alzheimer's disease using UPLC/ESI-Q-TOF mass spectrometry,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 1015-1016, pp. 50–61, 2016.
View at: Publisher Site | Google Scholar
N. Li, Y. Liu, W. Li et al., “A uplc/ms-based metabolomics investigation of the protective effect of ginsenosides rg1 and rg2 in mice with alzheimer’s disease,” Journal of Ginseng Research, vol. 40, no. 1, pp. 9–17, 2016.
View at: Publisher Site | Google Scholar
L. Whiley, A. Sen, J. Heaton et al., “Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease,” Neurobiology of Aging, vol. 35, no. 2, pp. 271–278, 2014.
View at: Publisher Site | Google Scholar
G. Paglia, M. Stocchero, S. Cacciatore et al., “Unbiased metabolomic investigation of Alzheimer's disease brain points to dysregulation of mitochondrial aspartate metabolism,” Journal of Proteome Research, vol. 15, no. 2, pp. 608–618, 2016.
View at: Publisher Site | Google Scholar
B. Ansoleaga, M. Jové, A. Schlüter et al., “Deregulation of purine metabolism in Alzheimer's disease,” Neurobiology of Aging, vol. 36, no. 1, pp. 68–80, 2015.
View at: Publisher Site | Google Scholar
S. F. Graham, C. Holscher, P. McClean, C. T. Elliott, and B. D. Green, “¹H NMR metabolomics investigation of an Alzheimer's disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma,” Metabolomics, vol. 9, no. 5, pp. 974–983, 2013.
View at: Publisher Site | Google Scholar
K. Fukuhara, A. Ohno, Y. Ota et al., “NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkers,” Journal of Clinical Biochemistry & Nutrition, vol. 52, no. 2, pp. 133–138, 2013.
View at: Publisher Site | Google Scholar
A. Alonso, S. Marsal, and A. JuliÃ, “Analytical methods in untargeted metabolomics: state of the art in 2015,” Frontiers in Bioengineering & Biotechnology, vol. 3, p. 23, 2015.
View at: Publisher Site | Google Scholar
A. K. Smilde, J. J. Jansen, H. C. Hoefsloot, R. A. Lamers, J. van der Greef, and M. E. Timmerman, “ANOVA-simultaneous component analysis (ASCA): a new tool for analyzing designed metabolomics data,” Bioinformatics, vol. 21, no. 13, pp. 3043–3048, 2005.
View at: Publisher Site | Google Scholar
C. C. Yde, J. J. Jansen, P. K. Theil, H. C. Bertram, and K. E. B. Knudsen, “Different metabolic and absorption patterns of betaine in response to dietary intake of whole-wheat grain, wheat aleurone or rye aleurone in catheterized pigs,” European Food Research and Technology, vol. 235, no. 5, pp. 939–949, 2012.
View at: Publisher Site | Google Scholar
M. Tremblay-Franco, N. J. Cabaton, C. Canlet et al., “Dynamic metabolic disruption in rats perinatally exposed to low doses of bisphenol-A,” PLoS ONE, vol. 10, no. 10, Article ID e0141698, 2015.
View at: Publisher Site | Google Scholar
H. Zheng, J. K. Lorenzen, A. Astrup et al., “Metabolic effects of a 24-week energy-restricted intervention combined with low or high dairy intake in overweight women: an NMR-based metabolomics investigation,” Nutrients, vol. 8, no. 3, p. 108, 2016.
View at: Publisher Site | Google Scholar
T. Kubo, S. Nishimura, Y. Kumagae, and I. Kaneko, “In vivo conversion of racemized β-amyloid ([D-Ser²⁶]Aβ1–40) to truncated and toxic fragments ([D-Ser²⁶]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients,” Journal of Neuroscience Research, vol. 70, no. 3, pp. 474–483, 2002.
View at: Publisher Site | Google Scholar
D. K. Rush, S. Aschmies, and M. C. Merriman, “Intracerebral/sB-amyloid(25–35) produces tissue damage: is it neurotoxic?” Neurobiology of Aging, vol. 13, no. 5, pp. 591–594, 1992.
View at: Publisher Site | Google Scholar
A. Diaz, D. Limon, R. Chávez, E. Zenteno, and J. Guevara, “Aβ_25–35 injection into the temporal cortex induces chronic inflammation that contributes to neurodegeneration and spatial memory impairment in rats,” Journal of Alzheimer's Disease, vol. 30, no. 3, pp. 505–522, 2012.
View at: Publisher Site | Google Scholar
S. Rosales-Corral, D.-X. Tan, R. J. Reiter, M. Valdivia-Velázquez, J. P. Acosta-Martínez, and G. G. Ortiz, “Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-β onto the hippocampus in vivo,” Journal of Neuroimmunology, vol. 150, no. 1-2, pp. 20–28, 2004.
View at: Publisher Site | Google Scholar
S. A. Litvinova, P. M. Klodt, V. S. Kudrin, V. B. Narkevich, and T. A. Voronina, “The behavior and neurotransmitter contents in brain structures of rats with Alzheimer’s disease modeled by administration of Aβ25–35,” Neurochemical Journal, vol. 9, no. 1, pp. 39–46, 2015.
View at: Publisher Site | Google Scholar
A. Díaz, L. De Jesús, L. Mendieta et al., “The amyloid-β_25–35 injection into the CA1 region of the neonatal rat hippocampus impairs the long-term memory because of an increase of nitric oxide,” Neuroscience Letters, vol. 468, no. 2, pp. 151–155, 2010.
View at: Publisher Site | Google Scholar
A. Nitta, A. Itoh, T. Hasegawa, and T. Nabeshima, “β-amyloid protein-induced Alzheimer's disease animal model,” Neuroscience Letters, vol. 170, no. 1, pp. 63–66, 1994.
View at: Publisher Site | Google Scholar
G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, 1989.
H. Zheng, L. Zhao, H. Xia et al., “NMR-based metabolomics reveal a recovery from metabolic changes in the striatum of 6-OHDA-induced rats treated with basic fibroblast growth factor,” Molecular Neurobiology, vol. 53, no. 10, pp. 6690–6697, 2016.
View at: Publisher Site | Google Scholar
F. Savorani, G. Tomasi, and S. B. Engelsen, “icoshift: a versatile tool for the rapid alignment of 1D NMR spectra,” Journal of Magnetic Resonance, vol. 202, no. 2, pp. 190–202, 2010.
View at: Publisher Site | Google Scholar
D. S. Wishart, T. Jewison, A. C. Guo et al., “HMDB 3.0- the human metabolome database in 2013,” Nucleic Acids Research, vol. 41, no. 1, pp. D801–D807, 2013.
View at: Publisher Site | Google Scholar
N. Psychogios, D. D. Hau, J. Peng et al., “The human serum metabolome,” PLoS ONE, vol. 6, no. 2, Article ID e16957, 2011.
View at: Publisher Site | Google Scholar
D. A. Butterfield, J. Drake, C. Pocernich, and A. Castegna, “Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide,” Trends in Molecular Medicine, vol. 7, no. 12, pp. 548–554, 2001.
View at: Publisher Site | Google Scholar
M. Yamada, T. Chiba, J. Sasabe et al., “Implanted cannula-mediated repetitive administration of Aβ25-35 into the mouse cerebral ventricle effectively impairs spatial working memory,” Behavioural Brain Research, vol. 164, no. 2, pp. 139–146, 2005.
View at: Publisher Site | Google Scholar
Z. Chen and C. Zhong, “Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies,” Progress in Neurobiology, vol. 108, pp. 21–43, 2013.
View at: Publisher Site | Google Scholar
H. Bachelard, “Brain energy metabolism,” Trends in Neurosciences, vol. 1, no. 3, p. XIV, 1978.
View at: Publisher Site | Google Scholar
L. Pellerin and P. J. Magistretti, “Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 22, pp. 10625–10629, 1994.
View at: Publisher Site | Google Scholar
A.-K. Bouzier-Sore, P. Voisin, P. Canioni, P. J. Magistretti, and L. Pellerin, “Lactate is a preferential oxidative energy substrate over glucose for neurons in culture,” Journal of Cerebral Blood Flow & Metabolism, vol. 23, no. 11, pp. 1298–1306, 2003.
View at: Google Scholar
M. T. Wyss, R. Jolivet, A. Buck, P. J. Magistretti, and B. Weber, “In vivo evidence for lactate as a neuronal energy source,” Journal of Neuroscience, vol. 31, no. 20, pp. 7477–7485, 2011.
View at: Publisher Site | Google Scholar
M. Wyss and R. Kaddurah-Daouk, “Creatine and creatinine metabolism,” Physiological Reviews, vol. 80, no. 3, pp. 1107–1213, 2000.
View at: Google Scholar
R. H. Andres, A. D. Ducray, U. Schlattner, T. Wallimann, and H. R. Widmer, “Functions and effects of creatine in the central nervous system,” Brain Research Bulletin, vol. 76, no. 4, pp. 329–343, 2008.
View at: Publisher Site | Google Scholar
R. M. Salek, J. Xia, A. Innes et al., “A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease,” Neurochemistry International, vol. 56, no. 8, pp. 937–947, 2010.
View at: Publisher Site | Google Scholar
S. M. De La Monte, E. Re, L. Longato, and M. Tong, “Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 30, supplement 2, pp. S217–S229, 2012.
View at: Publisher Site | Google Scholar
S. M. De La Monte, “Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease,” Frontiers in Bioscience (Elite Edition), vol. 4, pp. 1582–1605, 2012.
View at: Google Scholar
S. M. De La Monte, L. Longato, M. Tong, and J. R. Wands, “Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis,” Current Opinion in Investigational Drugs, vol. 10, no. 10, pp. 1049–1060, 2009.
View at: Google Scholar
R. González-Domínguez, T. García-Barrera, J. Vitorica, and J. L. Gómez-Ariza, “Deciphering metabolic abnormalities associated with Alzheimer's disease in the APP/PS1 mouse model using integrated metabolomic approaches,” Biochimie, vol. 110, pp. 119–128, 2015.
View at: Publisher Site | Google Scholar
K. Liu, X.-J. Ye, W.-Y. Hu et al., “Neurochemical changes in the rat occipital cortex and hippocampus after repetitive and profound hypoglycemia during the neonatal period: an ex vivo ¹H Magnetic Resonance Spectroscopy Study,” Molecular Neurobiology, vol. 48, no. 3, pp. 729–736, 2013.
View at: Publisher Site | Google Scholar
X. Zhang, H. Liu, J. Wu, X. Zhang, M. Liu, and Y. Wang, “Metabonomic alterations in hippocampus, temporal and prefrontal cortex with age in rats,” Neurochemistry International, vol. 54, no. 8, pp. 481–487, 2009.
View at: Publisher Site | Google Scholar
I. Barba, R. Fernandez-Montesinos, D. Garcia-Dorado, and D. Pozo, “Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics,” Journal of Cellular and Molecular Medicine, vol. 12, no. 5A, pp. 1477–1485, 2008.
View at: Publisher Site | Google Scholar
M. Marjanska, G. L. Curran, T. M. Wengenack et al., “Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 33, pp. 11906–11910, 2005.
View at: Publisher Site | Google Scholar
D. S. Dunlop, D. M. Mc Hale, and A. Lajtha, “Decreased brain N-acetylaspartate in Huntington's disease,” Brain Research, vol. 580, no. 1-2, pp. 44–48, 1992.
View at: Publisher Site | Google Scholar
J. Lalande, H. Halley, S. Balayssac et al., “¹H NMR metabolomic signatures in five brain regions of the AβPPswe Tg2576 mouse model of Alzheimer's disease at four ages,” Journal of Alzheimers Disease, vol. 39, no. 1, pp. 121–143, 2014.
View at: Publisher Site | Google Scholar
H.-Y. Liu, W.-Y. Gao, W. Wen, and Y.-M. Zhang, “Taurine modulates calcium influx through L-type voltage-gated calcium channels in isolated cochlear outer hair cells in guinea pigs,” Neuroscience Letters, vol. 399, no. 1-2, pp. 23–26, 2006.
View at: Publisher Site | Google Scholar
Y. Xiang, H. Gao, H. Zhu, N. Sun, Y. Ma, and H. Lei, “Neurochemical changes in brain induced by chronic morphine treatment: NMR studies in thalamus and somatosensory cortex of rats,” Neurochemical Research, vol. 31, no. 10, pp. 1255–1261, 2006.
View at: Publisher Site | Google Scholar
M. A. S. Di Leo, S. A. Santini, N. Gentiloni Silveri, B. Giardina, F. Franconi, and G. Ghirlanda, “Long-term taurine supplementation reduces mortality rate in streptozotocin-induced diabetic rats,” Amino Acids, vol. 27, no. 2, pp. 187–191, 2004.
View at: Publisher Site | Google Scholar
J. Zhou, Y. Li, G. Yan et al., “Protective role of taurine against morphine-induced neurotoxicity in C6 cells via inhibition of oxidative stress,” Neurotoxicity Research, vol. 20, no. 4, pp. 334–342, 2011.
View at: Publisher Site | Google Scholar
M. M. Mielke and C. G. Lyketsos, “Lipids and the pathogenesis of Alzheimer's disease: is there a link?” International Review of Psychiatry, vol. 18, no. 2, pp. 173–186, 2006.
View at: Publisher Site | Google Scholar
J. K. Yao, T. M. Wengenack, G. L. Curran, and J. F. Poduslo, “Reduced membrane lipids in the cortex of alzheimer's disease transgenic mice,” Neurochemical Research, vol. 34, no. 1, pp. 102–108, 2009.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2017 Yao Du et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1135

Downloads

1009

Citations

BioMed Research International

Early Effect of Amyloid β-Peptide on Hippocampal and Serum Metabolism in Rats Studied by an Integrated Method of NMR-Based Metabolomics and ANOVA-Simultaneous Component Analysis

Abstract

1. Introduction

2. Materials and Methods

2.1. Animals

2.2. Brain Stereotaxic Aβ25–35 Injection

2.3. Morris Water Maze (MWM) Test

2.4. Sample Collection and Preparation

2.5. NMR-Based Metabolomic Analysis

2.6. ANOVA-Simultaneous Component Analysis (ASCA)

3. Results

3.1. Impaired Learning and Memory in Rats after Aβ25–35 Injection

3.2. 1H NMR Metabolite Profiles of Hippocampus and Serum in Rats

3.3. Identification of Metabolic Changes in the Hippocampus and Serum of Rats after Aβ25–35 Injection Using ASCA

4. Discussion

4.1. Effect of Aβ25–35 Injection on Hippocampal Metabolism of Rats

4.2. Effect of Aβ25–35 Injection on Serum Metabolism of Rats

Competing Interests

Authors’ Contributions

Acknowledgments

References

Copyright

2.2. Brain Stereotaxic Aβ_25–35 Injection

3.1. Impaired Learning and Memory in Rats after Aβ_25–35 Injection

3.2. ¹H NMR Metabolite Profiles of Hippocampus and Serum in Rats

3.3. Identification of Metabolic Changes in the Hippocampus and Serum of Rats after Aβ_25–35 Injection Using ASCA

4.1. Effect of Aβ_25–35 Injection on Hippocampal Metabolism of Rats

4.2. Effect of Aβ_25–35 Injection on Serum Metabolism of Rats